Key Takeaways
- • Congressman Steve Cohen (TN-9) announced $2,525,665 in National Institutes of Health grants distributed across four projects at University of Tennessee Health Science Center and St. Jude Children's Research Hospital, with a focus on hearing loss research and related medical conditions.
- • The grant allocation includes funding for diabetes and kidney disease research, cancer treatment studies, and investigations into the effects of nicotine, demonstrating a diversified portfolio of biomedical research priorities.
- • Cohen's announcement reflects continued federal investment in regional medical research infrastructure, with St. Jude and UTHSC serving as anchor institutions for NIH-funded discovery in Tennessee.
- • According to Quiver Quantitative's financial disclosures, Cohen reported $84.2K in Q4 fundraising (filed January 31, 2026) and maintained $1.8M in cash on hand, positioning him for sustained constituent services and advocacy efforts.
Summary
Congressman Steve Cohen of Tennessee's 9th Congressional District announced the allocation of $2,525,665 in National Institutes of Health grants to two prominent medical research institutions in his district on April 14, 2026. The four grants were distributed between the University of Tennessee Health Science Center and St. Jude Children's Research Hospital, underscoring the federal government's continued commitment to biomedical research infrastructure in the Memphis region.
The funding encompasses multiple research initiatives addressing significant public health challenges. Specific projects include grants designated for diabetes and kidney disease research, studies focused on understanding cancer treatment mechanisms, and investigations into the physiological and pathological effects of nicotine exposure. This portfolio reflects the NIH's broad mandate to support foundational and applied research across diverse therapeutic areas.
Cohen characterized the grants as investments with meaningful potential for clinical translation. In public remarks, the congressman noted that these funds were positioned to "lead to new discoveries and potentially save lives," reflecting the dual imperatives of advancing scientific knowledge and delivering tangible health outcomes for patient populations.
From a fiscal perspective, Cohen's own fundraising activity for the same period showed $84.2K in disclosed contributions during Q4 2025, representing the 825th highest total among all congressional Q4 filings reviewed. Individual donors accounted for 30.5% of this total. His cash-on-hand position stood at $1.8M as of the filing date, ranking 230th among contemporary congressional disclosures and suggesting robust financial capacity for ongoing legislative and constituent operations.
The funding encompasses multiple research initiatives addressing significant public health challenges. Specific projects include grants designated for diabetes and kidney disease research, studies focused on understanding cancer treatment mechanisms, and investigations into the physiological and pathological effects of nicotine exposure. This portfolio reflects the NIH's broad mandate to support foundational and applied research across diverse therapeutic areas.
Cohen characterized the grants as investments with meaningful potential for clinical translation. In public remarks, the congressman noted that these funds were positioned to "lead to new discoveries and potentially save lives," reflecting the dual imperatives of advancing scientific knowledge and delivering tangible health outcomes for patient populations.
From a fiscal perspective, Cohen's own fundraising activity for the same period showed $84.2K in disclosed contributions during Q4 2025, representing the 825th highest total among all congressional Q4 filings reviewed. Individual donors accounted for 30.5% of this total. His cash-on-hand position stood at $1.8M as of the filing date, ranking 230th among contemporary congressional disclosures and suggesting robust financial capacity for ongoing legislative and constituent operations.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.